Search This Blog

Friday, March 17, 2023

Sangamo: Agreements terminated with Biogen, Novartis

 On March 13, 2023Novartis Institutes for BioMedical Research, Inc. ("Novartis") notified Sangamo Therapeutics, Inc. ("Sangamo") of its termination for convenience, effective June 11, 2023 (the "Novartis Termination Date"), of the Collaboration and License Agreement (the "Novartis Agreement") by and between Novartis and Sangamo dated July 27, 2020, pursuant to which Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategic review. Sangamo will investigate alternative options to advance the neurodevelopmental disorder programs that were subject to the Novartis Agreement, including potential development internally or with a collaboration partner, dependent on the outcome of a broader strategic review of its pre-clinical pipeline of therapies to treat patients suffering from central nervous system ("CNS") disorders.

On March 17, 2023Biogen MA, Inc. and its affiliate, Biogen International GmbH (together, "Biogen") notified Sangamo of its termination for convenience, effective June 15, 2023 (the "Biogen Termination Date"), of the Collaboration and License Agreement (the "Biogen Agreement") by and between Biogen and Sangamo dated February 26, 2020, pursuant to which Biogen and Sangamo were engaged in programs to research and develop gene regulation therapies to treat neurological diseases. Biogen has indicated to Sangamo that the termination relates to a recent strategic review. Sangamo will investigate alternative options to advance the neurological disease programs that were subject to the Biogen Agreement, including potential development internally or with a collaboration partner, dependent on the outcome of a broader strategic review of its pre-clinical pipeline of therapies to treat patients suffering from central nervous system ("CNS") disorders.

https://www.marketscreener.com/quote/stock/SANGAMO-THERAPEUTICS-INC-10811/news/SANGAMO-THERAPEUTICS-INC-Termination-of-a-Material-Definitive-Agreement-form-8-K-43276781/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.